CA2637315A1 - Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae - Google Patents

Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae Download PDF

Info

Publication number
CA2637315A1
CA2637315A1 CA002637315A CA2637315A CA2637315A1 CA 2637315 A1 CA2637315 A1 CA 2637315A1 CA 002637315 A CA002637315 A CA 002637315A CA 2637315 A CA2637315 A CA 2637315A CA 2637315 A1 CA2637315 A1 CA 2637315A1
Authority
CA
Canada
Prior art keywords
seq
variant
nucleic acid
encoding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002637315A
Other languages
English (en)
French (fr)
Inventor
Steven Boakes
Jesus Cortes Bargallo
Michael John Dawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Limited
Steven Boakes
Jesus Cortes Bargallo
Michael John Dawson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Limited, Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson filed Critical Novacta Biosystems Limited
Publication of CA2637315A1 publication Critical patent/CA2637315A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/365—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinoplanes (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/045—Actinoplanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002637315A 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae Abandoned CA2637315A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0600928.6A GB0600928D0 (en) 2006-01-17 2006-01-17 Improvements relating to lantibiotics
GB0600928.6 2006-01-17
PCT/GB2007/000138 WO2007083112A2 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Publications (1)

Publication Number Publication Date
CA2637315A1 true CA2637315A1 (en) 2007-07-26

Family

ID=35998187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002637315A Abandoned CA2637315A1 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Country Status (20)

Country Link
US (3) US7989416B2 (US07794700-20100914-C00152.png)
EP (2) EP1979375B9 (US07794700-20100914-C00152.png)
JP (1) JP5219837B2 (US07794700-20100914-C00152.png)
KR (1) KR101573536B1 (US07794700-20100914-C00152.png)
CN (1) CN101389641B (US07794700-20100914-C00152.png)
AT (1) ATE534659T1 (US07794700-20100914-C00152.png)
AU (1) AU2007206769B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0706525A2 (US07794700-20100914-C00152.png)
CA (1) CA2637315A1 (US07794700-20100914-C00152.png)
CY (1) CY1112559T1 (US07794700-20100914-C00152.png)
DK (1) DK1979375T3 (US07794700-20100914-C00152.png)
ES (1) ES2378090T3 (US07794700-20100914-C00152.png)
GB (1) GB0600928D0 (US07794700-20100914-C00152.png)
IL (1) IL192446A0 (US07794700-20100914-C00152.png)
MX (1) MX2008009047A (US07794700-20100914-C00152.png)
NZ (1) NZ569486A (US07794700-20100914-C00152.png)
PL (1) PL1979375T3 (US07794700-20100914-C00152.png)
PT (1) PT1979375E (US07794700-20100914-C00152.png)
SI (1) SI1979375T1 (US07794700-20100914-C00152.png)
WO (1) WO2007083112A2 (US07794700-20100914-C00152.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
JP5719312B2 (ja) * 2009-01-14 2015-05-13 ノヴァクタ バイオシステムズ リミティッド デオキシアクタガルジン誘導体
CA2750883A1 (en) * 2009-02-04 2010-08-12 Novacta Biosystems Limited Actagardine derivatives
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
TW201138800A (en) * 2010-02-02 2011-11-16 Novacta Biosystems Ltd Salts
CN103052383A (zh) * 2010-07-14 2013-04-17 诺瓦克塔生物系统有限公司 含有b型羊毛硫抗生素的制剂
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US9975930B2 (en) 2012-11-30 2018-05-22 Naicons S.R.L. Lantibiotic derivatives and process for their preparation
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) * 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (US07794700-20100914-C00152.png) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
PT700998E (pt) 1994-09-12 2004-03-31 Aventis Pharma Gmbh Mersacidina recombinante e metodo para a sua producao
JP4236699B2 (ja) 1995-06-23 2009-03-11 アンビィー インコーポレイテッド 抗生物質抵抗性グラム陽性細菌の制御および感染治療の方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
GB0110432D0 (en) * 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2004033706A2 (en) 2002-10-10 2004-04-22 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
WO2005014628A1 (en) 2003-07-18 2005-02-17 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof.
WO2005079508A2 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
CA2623624A1 (en) 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
AU2007310534A1 (en) 2006-10-27 2008-05-02 Capsugel Belgium Nv Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2010058238A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
JP5719312B2 (ja) 2009-01-14 2015-05-13 ノヴァクタ バイオシステムズ リミティッド デオキシアクタガルジン誘導体
CA2750883A1 (en) 2009-02-04 2010-08-12 Novacta Biosystems Limited Actagardine derivatives
EP2216937A1 (en) 2009-02-10 2010-08-11 Alcatel Lucent Alarm notification between customer premises equipment and a remote management server

Also Published As

Publication number Publication date
JP5219837B2 (ja) 2013-06-26
KR20080086517A (ko) 2008-09-25
PT1979375E (pt) 2012-03-06
CN101389641B (zh) 2013-06-05
US20100048459A1 (en) 2010-02-25
EP2189472A1 (en) 2010-05-26
NZ569486A (en) 2011-07-29
DK1979375T3 (da) 2012-03-19
WO2007083112A3 (en) 2008-05-08
ATE534659T1 (de) 2011-12-15
GB0600928D0 (en) 2006-02-22
US7989416B2 (en) 2011-08-02
EP1979375B9 (en) 2012-05-09
MX2008009047A (es) 2008-12-18
AU2007206769A1 (en) 2007-07-26
WO2007083112A2 (en) 2007-07-26
BRPI0706525A2 (pt) 2011-03-29
AU2007206769B2 (en) 2013-06-20
CY1112559T1 (el) 2016-02-10
EP1979375A2 (en) 2008-10-15
IL192446A0 (en) 2008-12-29
US8465947B2 (en) 2013-06-18
US20110306091A1 (en) 2011-12-15
JP2009523777A (ja) 2009-06-25
SI1979375T1 (sl) 2012-03-30
PL1979375T3 (pl) 2012-04-30
ES2378090T3 (es) 2012-04-04
CN101389641A (zh) 2009-03-18
KR101573536B1 (ko) 2015-12-11
EP1979375B1 (en) 2011-11-23
USRE45003E1 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
USRE45003E1 (en) Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae
US20140038297A1 (en) Genes and Proteins for the Biosynthesis of the Lantibiotic 107891
EP2647647A2 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
WO1999005283A2 (fr) Genes de biosynthese et de transfert des 6-desoxyhexoses chez saccharopolyspora erythraea et chez streptomyces antibioticus et leur utilisation
JP7086984B2 (ja) Ｓｔｒｅｐｔｏｍｙｃｅｓ ｆｕｎｇｉｃｉｄｉｃｕｓの遺伝子組換え株におけるエンデュラシジンの産生を増強するための組成物及び方法
US20080145892A1 (en) Genes and Proteins For the Biosynthesis of the Glycopeptide Antibiotic A40926
RU2441915C2 (ru) Гены и белки для биосинтеза лантибиотика 107891
WO2006111743A2 (en) Identifying lantibiotic gene clusters and novel lantibiotic genes
Spohn Exploiting gene regulation as an approach to identify, analyze and utilize the biosynthetic pathways of the glycopeptide ristomycin A and the zincophore [S, S]-EDDS in Amycolatopsis japonicum
Bell Analysis and manipulation of “actagardine” gene clusters from Actinoplanes
FR2786201A1 (fr) Genes de biosynthese et de transfert des 6-desoxy-hexoses chez saccharopolyspora erythraea et chez streptomyces antibioticus et leur utilisation
FR2786189A1 (fr) Genes de biosynthese et de transfert des 6-desoxy-hexoses chez saccharopolyspora erythraea et chez streptomyces antibioticus et leur utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170118